Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy by Wang, Xuejuan et al.
ORIGINAL ARTICLE
Comprehensive evaluation of a somatostatin-based radiolabelled
antagonist for diagnostic imaging and radionuclide therapy
Xuejuan Wang & Melpomeni Fani & Stefan Schulz &
Jean Rivier & Jean Claude Reubi & Helmut R. Maecke
Received: 1 March 2012 /Accepted: 9 August 2012 /Published online: 29 August 2012
# Springer-Verlag 2012
Abstract
Purpose Targeting of tumours positive for somatostatin
receptors (sst) with radiolabelled peptides is of interest for
tumour localization, staging, therapy follow-up and targeted
radionuclide therapy. The peptides used clinically are exclu-
sively agonists, but recently we have shown that the radio-
labelled somatostatin-based antagonist 111In-DOTA-sst2-
ANT may be preferable to agonists. However, a compre-
hensive study of this radiolabelled antagonist to determine
its significance was lacking. The present report describes the
evaluation of this novel antagonist labelled with 111In and
177Lu in three different tumour models.
Methods Radiopeptide binding, internalization and dissocia-
tion studies were performed using cells expressing HEK293-
rsst2. Biodistribution studies were performed in HEK293-
rsst2, HEK293-hsst2 and HEK293-rsst3 xenografted mice.
Results Saturation binding analysis confirmed earlier IC50
data for 111/natIn-DOTA-sst2-ANTand showed similar affinity
of 177/natLu-DOTA-sst2-ANT for the sst2. Only low internal-
ization was found in cell culture (6.68±0.06 % at 4 h), which
was not unexpected for an antagonist, and this could be further
reduced by the addition of sucrose. No internalization was
observed in HEK293 cells not expressing sst. Both results
indicate that the internalization was specific. 111In-DOTA-
sst2-ANT and 177Lu-DOTA-sst2-ANT were shown to target
tumour xenografts expressing the rat and the human sst2
receptor with no differences in their uptake or pharmacokinet-
ics. The uptake in rsst2 and hsst2 was high (about 30%IA/g 4 h
after injection) and surprisingly long-lasting (about 20–23
%IA/g 24 h after injection). Kidney uptake was blocked by
approximately 50 % by lysine or Gelofusine.
Conclusion These results indicate that radiolabelled
somatostatin-based antagonists may be superior to
corresponding agonists. The long tumour retention time of
177Lu-DOTA-sst2-ANT indicates that this new class of com-
pounds is of relevance not only in diagnostic imaging but also
in targeted radionuclide therapy of sst-positive tumours.
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Introduction
Receptors for regulatory peptides have been found to be
overexpressed in a variety of human tumours. This led to
the idea to develop radiolabelled peptides and use them in
sensitive imaging modalities such as single photon emission
computed tomography (SPECT) and positron emission to-
mography (PET) for tumour imaging, and to design cyto-
toxic agents that could be used in targeted cancer treatment.
The prototypes of these peptides are based on somatostatin
[1, 2], targeting somatostatin receptors (sst), most impor-
tantly the subtype 2 (sst2). The consensus was that success-
ful in vivo tumour targeting requires the use of receptor
agonists as they are internalized and therefore have a long
retention time in the tumour, an important prerequisite for
targeted radionuclide therapy if longer-lived β- emitters
such as 90Y or 177Lu are being used.
This hypothesis appeared to be supported by recent data
reported by Storch et al. [3]. They have shown that there is a
good correlation between tumour uptake as well as uptake in
sst-positive organs (e.g. pancreas) and the rate of internali-
zation into sst2-expressing cells in culture. Fani et al. [4]
have shown that high affinity but slowly internalizing bicy-
clic somatostatin agonists have relatively low uptake and
fast washout from sst-positive tumours in vivo. In addition,
Ginj et al. [5] studied a series of radiolabelled DOTA-
conjugated pansomatostatin analogues (carbocyclic octapep-
tides) which showed high affinity for sst1–sst5 and agonistic
potency if studied using an adenylate cyclase activity assay.
The agonistic properties of the pansomatostatin peptides were
tested in terms of their effect on forskolin-stimulated cAMP
accumulation. EC50 values obtained from this assay were
shown to be comparable with those of the natural
somatostatin-28 (SS-28). Surprisingly, these radioligands
showed efficient internalization only in cell lines expressing
sst3; inefficient or no internalization was found in cell lines
expressing sst2 and sst5. As a consequence in a dual tumour
model only sst3-expressing tumours showed high and persis-
tent tumour uptake, whereas sst2-expressing tumours showed
low uptake and fast washout [5]. Contrary to these results, we
have recently found that potent radiolabelled sst2 and sst3
antagonists show higher in vivo tumour uptake as well as
tumour-to-normal tissue ratios than radiolabelled agonists of
similar or even higher receptor affinity [6]. The 111In-labelled
antagonist DOTA-sst2-ANT (where sst2-ANT is 4-NO2-
Phe-c(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2) showed
high tumour uptake in HEK-sst2 xenografts and surprisingly
long retention, despite the fact that very little internalization
was detected [6].
Somewhat contrary to these data, Wadas et al. con-
cluded from their studies with two 64Cu-labelled
somatostatin-based peptides that the agonist 64Cu-CB-
TE2A-TATE shows somewhat higher tumour uptake
than 64Cu-CB-TE2A-sst2-ANT despite the fact that there
was about a 14-fold difference in receptor binding sites in
their rat pancreatic AR42J cell line in favour of the antagonist
[7], similar to our findings in a transfected cell line HEK293-
rsst2 [6]. The much lower affinity of the antagonist compared
to the agonist may be the reason for these findings.
We therefore decided to study this radiopeptide more
thoroughly, and extended the pharmacokinetics to later
time-points in order to investigate the potency of these
new radiolabelled antagonists as therapeutic radiopharma-
ceuticals. Therefore we also extended the study using 177Lu
and studied the biodistribution of 177Lu-DOTA-sst2-ANT to
determine if the radiometal has an influence on the pharma-
cokinetics of this new class of radiopeptides, which is pos-
sible due to the potential differences in the geometry of the
radiometal complexes. We also looked into the possibility of
blocking the tubular cell-mediated kidney uptake of antag-
onistic radiopeptides with agents that are successfully used
clinically with the corresponding radiolabelled agonists.
Finally, we studied 111In-DOTA-sst2-ANT in a different
tumour model, namely a subcutaneous mouse xenograft
model with HEK293-cell lines expressing the human sst2
receptor rather than the rat receptor exclusively used in the
earlier study to exclude species differences as found with
gastrin-releasing peptide receptor targeting bombesin deriv-
atives [8].
Materials and methods
Preparation of radiotracers
DOTA-sst2-ANT was synthesised as described previously
[9, 10]. The 111In- and 177Lu-DOTA-sst2-ANT were pre-
pared after incubation of 5 μg DOTA-sst2-ANT in 300 μL
sodium acetate buffer (0.4 M, pH5) with 111InCl3 or
177LuCl3 (37–74 MBq), respectively, at 95 °C for 30 min.
Quality control was performed by RP-HPLC, as previously
described [4].
For all in vitro studies excess of natInCl3·5H2O was added
after the formation of 111In-DOTA-sst2-ANT and the reac-
tion mixture was incubated at 95 °C for an additional 30 min
to form homogeneous 111/natIn-DOTA-sst2-ANT solution.
For the in vivo studies the solutions of 111In-DOTA-sst2-
ANT and 177Lu-DOTA-sst2-ANT were prepared by dilution
with 0.9 % NaCl/0.1 % BSA.
Cell lines
Cells of the transfected HEK293 cell line stably expressing
the rat sst2 and sst3 receptors (HEK293-rsst2 and HEK293-
rsst3) and the human sst2 receptor (HEK293-hsst2) were
used in the in vitro and in vivo studies. HEK293 cells
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without transfection were used as negative control. All
transfected cells were cultured at 37 °C in an atmosphere
containing 5 % CO2 in DMEM containing 10 % FBS,
100 U/mL penicillin, 100 μg/mL streptomycin and
500 μg/mLG418. The nontransfected HEK293 cells were
cultured in the same medium without G418. Culture
reagents were supplied by BioConcept (Allschwil,
Switzerland).
Determination of the sst affinity
Affinity was determined on HEK293-rsst2 cell membranes.
Briefly, the cells were rinsed with cold PBS (pH7.4), resus-
pended in homogenization buffer (20 mM Tris-HCl, 1 mM
ethylenediaminetetraacetic acid, 0.25 M sucrose, pH7.6)
with protease and phosphatase inhibitors (1 mg/mL bacitra-
cin, 0.1 mg/mL soybean trypsin inhibitor, 0.125 mg/mL
phenylmethylsulphonyl fluoride) and lysed using a homog-
enizer on ice. After low-speed centrifugation (500 g, 5 min),
the supernatants were collected and centrifuged at 20,000 g
for 50 min to separate the cell membranes. Membranes were
suspended in HEPES buffer using a homogenizer. Protein
content was determined using the Bradford reagent (Bio-
Rad Laboratories, Marnes La Coquette, France) using BSA
as a standard.
Saturation binding studies were performed in quadrupli-
cate in 96-well plates (10 μg cell membrane per well) using
a MultiScreen®HTS-96 assay system (Millipore, Billerica,
MA). Increasing concentrations of 111/natIn-DOTA-sst2-
ANT and 177/natLu-DOTA-sst2-ANT, ranging from 0.05
nM to 100 nM, were prepared with the binding buffer
(150 mM HEPES, 10 mM MgCl2, 14 mg/L bacitracin,
0.3 %w/v BSA, pH7.6). After the addition of the radio-
peptide to the membranes with or without a 1,000-fold
excess of DOTA-sst2-ANT to determine nonspecific bind-
ing, the plates were shaken for 2 h at room temperature. The
membranes were then washed three times with binding
buffer and measured in a γ-counter (Packard, Cobra II).
Specific binding was calculated by subtracting nonspecific
from total binding at each radiopeptide concentration. Dis-
sociation constants (Kd) and maximum numbers of binding
sites (Bmax) values were calculated from Scatchard plots
using Origin 7.5 software (Microcal Software, Northamp-
ton, MA).
Internalization studies
Internalization of 111/natIn-DOTA-sst2-ANT was investigat-
ed under four different conditions. Initially, the specific
internalization of 111/natIn-DOTA-sst2-ANT was determined
in HEK293-rsst2 cells at 37 °C. The same experiment was
repeated with HEK293-rsst2 cells pretreated with 0.5 M
sucrose for 30 min before the addition of the radiopeptide
to determine whether the internalization was via receptor-
mediated endocytosis. The experiment was also carried out
in HEK293 cells without receptors and finally the experi-
ment was performed at 4 °C to prevent internalization.
All experiments were performed in six-well plates. Brief-
ly, approximately 2.5 pmol of 111/natIn-DOTA-sst2-ANTwas
added to the medium and the cells (106 cells per well) and
incubated (in triplicate) for 0.5, 1, 2 and 4 h at 37 °C in an
atmosphere containing 5 % CO2 (or 4 °C in the last exper-
imental condition). Nonspecific surface-bound and internal-
ized radiopeptide were determined in the presence of a
1,000-fold excess of DOTA-sst2-ANT. The final volume
was 1.5 mL per well. At the indicated time-points the
cellular uptake was stopped by removal of the medium
followed by washing the cells with ice-cold PBS (pH7.4).
Cells were then treated for 5 min (three times) with glycine
buffer (0.05 mol/L glycine solution, pH2.8) to distinguish
between cell surface-bound radiopeptide (acid-releasable)
and internalized radiopeptide (acid-resistant). Finally, the
cells were detached from the plates by incubation with
1 M NaOH for 10 min at 37 °C. The radioactivity of all
fractions was measured in the γ-counter.
Dissociation studies
The dissociation of 111/natIn-DOTA-sst2-ANT was stud-
ied in HEK293-rsst2 cells under two different design
settings. In the first study, approximately 2.5 pmol of
111/natIn-DOTA-sst2-ANT was added to the cells fol-
lowed by incubation for 3 h on ice. The low tempera-
ture prevents internalization while the long incubation
time ensures equilibrium. After 3 h the unbound radio-
peptide was rinsed off with cold medium and the cells
were treated with 0.9 mL of prewarmed medium
(DMEM containing 1 % FBS) along with 0.1 mL of
DOTA-sst2-ANT (50 or 250 pmol) or 0.1 mL PBS. The
six-well plates were then immediately transferred to
37 °C. After 5 min the whole medium, which contained
the dissociated radiopeptide, was quickly removed for
quantification. The same amount of medium with or
without DOTA-sst2-ANT, as described above, was
added to the cells and incubated until the next time-
point. This procedure was repeated for all investigated
time-points (5, 10, 15, 30 and 60 min). The surface-
bound fractions were obtained as described above and
quantified in the γ-counter.
In the second study, HEK293-rsst2 cells were treated
with different amounts of 111/natIn-DOTA-sst2-ANT (0.2,
0.5, 1.0 and 2.5 pmol) for 3 h on ice and the unbound
radioligand was then rinsed off. Fresh pre-warmed me-
dium (1 mL) was added to each well followed by
incubation for 5, 10, 15, 30, 40 and 60 min (37 °C in
an atmosphere containing 5 % CO2). At each time-point
1878 Eur J Nucl Med Mol Imaging (2012) 39:1876–1885
the medium, which contained the dissociated radioli-
gand, was quickly removed for quantification and fresh
medium was added.
Animal models
All animal studies were performed in accordance with
the guidelines of Swiss regulations (approval 789).
Athymic female nude mice at 4–5 weeks of age were
implanted subcutaneously (s.c.) in the right shoulder
with 107 HEK293-rsst2 or HEK293-hsst2 cells freshly
suspended in sterile PBS. A dual tumour model was
also used in which mice were implanted with 107
HEK293-rsst2 in the right shoulder and 10
7 HEK293-
rsst3 in the left shoulder. As HEK293-rsst3 cells grow
somewhat faster, they were implanted 3 days later than
the HEK293-rsst2 cells. Tumours were allowed to grow for
approximately 2 weeks to reach a diameter of 8–10 mm.
Biodistribution of 111In-DOTA-sst2-ANT
and 177Lu-DOTA-sst2-ANT
Nude mice were injected into the tail vein with 0.1 mL of a
10-pmol solution of 111In- or 177Lu-DOTA-sst2-ANT (ap-
proximately 0.2 MBq). For the determination of nonspecific
uptake in the tumour or sst2 receptor-positive organs, a
group of mice were injected with a mixture of 10 pmol
radiopeptide with 20 nmol DOTA-sst2-ANT. At preselected
time-points mice were killed and dissected. The biodistribu-
tion of 111In-DOTA-sst2-ANT was studied in the dual
HEK293-rsst2/HEK293-rsst3 xenografted mice at 30 min
and 4, 24, 48 and 72 h after injection (p.i.) and in
HEK293-hsst2 xenografted mice at 1, 4, 24, 48 and 72 h
p.i. The biodistribution of 177Lu-DOTA-sst2-ANTwas stud-
ied in HEK293-rsst2 xenografted mice at 4, 24, 48 and 72 h
p.i. Organs of interest were collected, rinsed of excess
blood, weighed and counted in the γ-counter together with
the injection standards. The percentage of injected activity
per gram tissue (%IA/g) was calculated for each tissue.
Blocking of renal uptake
The plasma expander Gelofusine, a succinylated gelatin
solution (40 mg/mL) and a lysine solution containing
200 mg/mL in PBS were used in an attempt to reduce the
kidney uptake of 111In-DOTA-sst2-ANT. HEK293-rsst2
xenografted mice were intravenously injected with Gelofu-
sine (4 mg) or lysine (20 mg) into the tail vein. Two other
injected doses were also used (6 mg of Gelofusine and
30 mg of lysine per animal). 111In-DOTA-sst2-ANT
(0.1 mL of a 10-pmol solution, approximately 0.2 MBq)
was injected 5 min later. Animals were killed 24 h p.i. and
biodistribution studies were performed as described above.
Statistical analysis
Values are presented as means ± SD. Student’s t test was
used to determine statistical significance. The significance
level was set at 0.05.
Results
Chemistry and radiochemistry
The synthesis and characterization of the DOTA-sst2-ANT
was according to published procedures [4, 9, 10]. The purity
of the peptide as determined by HPLC was >97 %. 111In-
and 177Lu-DOTA-sst2-ANT were prepared in high labelling
yield and radiochemical purity (>95 %) at specific activities
of 10–20 MBq/nmol.
In vitro binding and internalization studies
Figure 1 shows the Scatchard analysis of 111/natIn-DOTA-
sst2-ANT on HEK-rsst2 cell membranes. The calculated
dissociation constant (Kd) was 5.78±0.64 nM and the cal-
culated maximum number of binding sites (Bmax) was
37.6±1.2 pmol/mg. Statistical analysis showed a significant
correlation (Pearson correlation coefficient r0−0.9726 and
R200.9460). The dissociation constant of 177/natLu-DOTA-
sst2-ANT was similar (Kd08.16±0.90 nM).
The internalization properties of 111/natIn-DOTA-sst2-
ANT were initially studied after incubation of HEK293-
rsst2 cells with the radiopeptide at 37 °C in the absence or
presence of a 1,000-fold excess of DOTA-sst2-ANT
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Fig. 1 Saturation binding study on HEK293-rsst2 cell membranes,
using increased concentrations of 111/natIn-DOTA-sst2-ANT, ranges
from 0.05 to 100 nM. The dissociation constants (Kd) and maximum
numbers of binding sites (Bmax) were calculated using Origin 7.5
software. All data are from quadruplicate experiments
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(nonspecific uptake). Specific internalization over time is
shown in Fig. 2. 111/natIn-DOTA-sst2-ANT showed low
internalization. At 4 h, only 6.68±0.06 % of the radiopep-
tide was internalized, which corresponds to the plateau,
while 30.63±0.28 % was bound on the cell surface (data
not shown). Figure 2 shows the internalization of 111/natIn-
DOTA-sst2-ANT under the various experimental settings.
Pretreatment of the cells with hypertonic sucrose (0.5 M) or
incubation at 4 °C significantly reduced or even prevented
the internalization of 111/natIn-DOTA-sst2-ANT. The inter-
nalized fraction at 4 h dropped from 6.68±0.06 % (37 °C) to
2.66±0.05 % when the cells were pretreated with sucrose
and to 0.83±0.14 % when the cells were incubated at 4 °C.
No internalization of 111/natIn-DOTA-sst2-ANTwas found in
the nontransfected HEK293 cells.
Dissociation studies
The disappearance of 111/natIn-DOTA-sst2-ANT from the
receptors was evaluated in HEK293-rsst2 cells which
were treated with PBS, or with 50 pmol or 250 pmol
of DOTA-sst2-ANT, as described in Materials and methods.
The dissociation profiles are shown in Fig. 3a. A rela-
tively slow release of the cell-associated radioactivity
was found if no DOTA-sst2-ANT was added to the
fresh medium (cells treated with PBS); 56.5±2.6 % of
the radiopeptide was detected in the medium after
60 min. The addition of 50 pmol or 250 pmol of
DOTA-sst2-ANT to the medium (to inhibit rebinding
of the radiopeptide) led to an irreversible dissociation
with a t1/2 of about 10 min. Within the first 15 min,
81.9±7.0 % and 88.6±3.5 % of the radiopeptide had
dissociated from the sst2 receptors when 50 pmol and
250 pmol DOTA-sst2-ANT was added, respectively, and
at 60 min almost all the radiopeptide has dissociated
(93.5±4.1 % and 94.6±3.7 %, respectively; Fig. 3a).
We also determined whether the different concentrations
of 111/natIn-DOTA-sst2-ANT had any influence on the dis-
sociation rate of the radiopeptide from the receptors. The
results are summarized in Fig. 3b. No significant differences
were observed in the dissociation rates of 111/natIn-DOTA-
sst2-ANT in the range of 0.2 to 1.0 pmol/mL. However,
significantly higher values were found over time when the
cells were treated with the highest concentration (2.5 pmol/
mL) of 111/natIn-DOTA-sst2-ANT.
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Fig. 2 Specific internalization rates of 111/natIn-DOTA-sst2-ANT into
HEK293-rsst2 cells incubated at 37 °C (squares), into HEK293-rsst2
cells pretreated with 0.5 M sucrose and incubated at 37 °C (triangles),
into HEK293-rsst2 cells incubated at 4 °C (circles) and into HEK293
cells incubated at 37 °C (diamond). The results are expressed as
specific internalization (percentage of dose added to 1 million cells).
All data are from three independent experiments performed in triplicate
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Fig. 3 Dissociation of 111/natIn-DOTA-sst2-ANT from HEK293-rsst2
cells at 37 °C. a 2.5 pmol of 111/natIn-DOTA-sst2-ANT was allowed to
bind to the receptors on the cell surface at 4 °C and after removal of the
unbound radiopeptide, the cells were treated with PBS (squares), or
with 50 pmol (circles) or 250 pmol (triangles) DOTA-sst2-ANT at 37 °
C. b 0.2 pmol (diamonds), 0.5 pmol (triangles), 1.0 pmol (squares) and
2.5 pmol (circles) 111/natIn-DOTA-sst2-ANTwas allowed to bind to the
receptors on the cell surface at 4 °C and after removal of the unbound
radiopeptide, the cells were incubated with fresh medium at 37 °C. At
each time-point the percentage of radiopeptide which had dissociated
from the receptors was calculated and plotted
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Biodistribution studies
Biodistribution studies of 111In-DOTA-sst2-ANT in a dual
tumour model bearing HEK293-rsst2 and HEK293-rsst3
tumours were carried out from 30 min up 72 h p.i. The
results are summarized in Tables 1 and 2. At the initial time-
point of the study, 111In-DOTA-sst2-ANT had accumulated
in the kidneys, the sst2-positive organs including the stom-
ach and pancreas, and into the rsst2-expressing tumours. The
blood clearance was fast (blood values were reduced by
95 % from 30 min to 4 h) and a fast washout was observed
from all nontarget organs, including the stomach and pan-
creas, where more than 90 % was washed out within 4 h.
The accumulation of 111In-DOTA-sst2-ANT in the rsst2-
expressing tumours reached a peak at 4 h (29.12±3.90
%IA/g) and remained high at 24 h p.i. (22.84±0.40 %IA/
g). The washout from the rsst2-tumours was relatively slow:
about 50 % still remained in the tumour at 48 h p.i. (13.00±
1.89 %IA/g) and about 25 % at 72 h p.i. (7.00±0.87 %IA/g).
The specificity of the uptake in rsst2-tumours was confirmed
by the very low uptake found in rsst3-expressing tumours
(0.34±0.06 %IA/g, 4 h p.i.) under the same conditions. In
addition the blocking experiment performed 4 h p.i. (coin-
jection of excess DOTA-sst2-ANT) showed a reduction in
tumour uptake by almost 90 %, and this was also the case
for sst2-expressing tissues, such as the pancreas, while the
low uptake in the rsst3-expressing tumours remained unaf-
fected. Tumour-to-blood and tumour-to-muscle ratios in-
creased significantly over time, while tumour-to-kidney
ratios increasing almost threefold from 30 min up to 4 h,
and remaining unchanged over 48 h.
In order to exclude species differences, biodistribution
studies of 111In-DOTA-sst2-ANT were performed in mice
bearing human sst2-expressing tumours (HEK293-hsst2).
The results are summarized in Tables 3 and 4. The biodis-
tribution profile and pharmacokinetics of 111In-DOTA-sst2-
ANT in HEK293-hsst2 xenografted mice were found to be
very similar to those in HEK293-rsst2 xenografted mice.
111In-DOTA-sst2-ANT accumulated in the kidneys, stom-
ach, pancreas (between 7 and 13 %IA/g) and into the hsst2-
expressing tumours (25.26±4.00 %IA/g) at 1 h p.i. The
uptake in all other organs was much lower (between 0.6
and 2.6 %IA/g). The uptake in the hsst2 tumours was the
same as in the rsst2 tumours, reaching a peak at 4 h (29.61±
5.13 %IA/g) and showing the same washout rate as de-
scribed above (see also Fig. 4). The specificity of 111In-
DOTA-sst2-ANT for the human sst2 receptors was con-
firmed by blocking experiments, where tumour uptake was
reduced by more than 95 % when a 2,000-fold excess of
DOTA-sst2-ANT was coinjected.
The biodistribution profile of DOTA-sst2-ANT was ad-
ditionally evaluated in HEK293-rsst2 xenografted mice us-
ing the therapeutic radionuclide 177Lu. The biodistribution
results of 177Lu-DOTA-sst2-ANT are summarized in
Tables 5 and 6. A higher uptake of 177Lu-DOTA-sst2-ANT
was observed in some organs, including the pancreas, the
adrenals and the gastrointestinal tract (stomach and intes-
tines), where the somatostatin binding sites are located. The
Table 1 Biodistribution (mean ±
SD %IA/g, n04) of 111In-DOTA-
sst2-ANT in nude mice simulta-
neously bearing HEK-rsst2 and
HEK-rsst3 tumours
aCoinjection of 20 nmol DOTA-
sst2-ANT.
Organ 30 min 4 h 4 h blockinga 24 h 48 h 72 h
Blood 2.76±0.19 0.14±0.03 0.13±0.01 0.05±0.01 0.01±0.00 0.01±0.00
Heart 1.23±0.05 0.11±0.03 0.08±0.01 0.04±0.00 0.03±0.01 0.02±0.01
Liver 1.74±0.18 0.43±0.07 0.49±0.03 0.32±0.02 0.26±0.02 0.24±0.05
Spleen 1.67±0.23 0.23±0.04 0.21±0.02 0.15±0.02 0.11±0.01 0.12±0.03
Lung 6.79±2.01 0.46±0.22 0.32±0.04 0.17±0.01 0.10±0.03 0.04±0.03
Kidney 22.92±2.62 10.50±1.00 9.67±1.38 7.38±0.09 4.33±0.56 2.96±0.35
Stomach 7.82±2.03 0.61±0.18 0.19±0.07 0.25±0.06 0.16±0.02 0.14±0.02
Intestine 1.72±0.25 0.16±0.03 0.15±0.03 0.08±0.03 0.05±0.02 0.03±0.01
Adrenals 4.74±3.00 0.49±0.12 0.24±0.04 0.46±0.26 0.12±0.03 0.03±0.03
Pancreas 24.16±6.58 0.71±0.21 0.09±0.02 0.13±0.02 0.07±0.02 0.06±0.01
Muscle 0.97±0.36 0.11±0.02 0.09±0.02 0.06±0.03 0.03±0.01 0.03±0.01
Bone 1.84±0.38 1.29±0.75 0.58±0.22 0.48±0.14 0.18±0.08 0.15±0.03
Tumour
rsst2 22.33±3.27 29.12±3.90 3.62±0.26 22.84±0.40 13.00±1.89 7.00±0.87
rsst3 2.92±0.91 0.34±0.06 0.30±0.04 0.14±0.03 0.06±0.03 0.06±0.02
Table 2 Tumour-to-nontumour ratios of 111In-DOTA-sst2-ANT in
nude mice bearing HEK-rsst2 tumours
Ratio 30 min 4 h 24 h 48 h 72 h
Tumour-to-blood 8.1 205 440 969 1199
Tumour-to-muscle 23 263 381 488 233
Tumour-to-liver 13 67 72 51 29
Tumour-to-kidney 1.0 2.8 3.1 2.4
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uptake of 177Lu-DOTA-sst2-ANT in rsst2-tumours was
slightly higher at 4 h p.i. (34.90±2.86 %IA/g) than that of
111In-DOTA-sst2-ANT, but the difference was not statisti-
cally significant (p>0.05). The specificity of 177Lu-DOTA-
sst2-ANT for the rsst2 was also confirmed by blocking
experiments with coinjection of a 2,000-fold excess of
DOTA-sst2-ANT which led to a reduction of more than
95 % of the radioactivity in the tumour. The washout of
177Lu-DOTA-sst2-ANT from the tumour was relatively
slow and very similar to that of 111In-DOTA-sst2-ANT.
Blocking of renal uptake
The influence of Gelofusine and lysine on renal uptake of
111In-DOTA-sst2-ANT in HEK293-rsst2 xenografted mice
was studied in comparison to mice without any intervention
24 h p.i. The biodistribution results are summarized in
Fig. 5. Injection of lysine, Gelofusine or PBS (control
group) resulted in similar 111In-DOTA-sst2-ANT concentra-
tions in all tissues and organs except for kidneys. Compared
to the control group, intravenous administration of 4 mg of
Gelofusine reduced kidney uptake from 7.38±0.09 %IA/g
(control group) to 4.36±0.27 %IA/g. Similarly, the admin-
istration of 20 mg lysine reduced kidney uptake from 7.38±
0.09 %IA/g (control group) to 3.84±0.27 %IA/g. The use of
higher injected doses of Gelofusine (6 mg) and lysine
(30 mg) resulted in a similar reduction in kidney uptake
(3.58±0.44 and 3.69±0.44 %IA/g, respectively). No statis-
tically significant difference was found between animals
injected with lysine and those injected with Gelofusine.
The injection of lysine or Gelofusine did not affect the
tumour uptake resulting in an increase of tumour-to-kidney
ratio by a factor of 2.
Discussion
We have recently shown that the somatostatin-based radio-
antagonist 111In-DOTA-sst2-ANT shows superior pharma-
cokinetic properties to the agonists 111In-DTPA-TATE and
111In-DOTA-NOC in rat sst2 xenografted mice [6]. We
found not only higher tumour uptake but also surprisingly
high retention over 24 h. The same pharmacokinetics were
not found with 64Cu-CB-TE2A-sst2-ANT compared with
Table 3 Biodistribution (mean ±
SD %IA/g, n04) of 111In-DOTA-
sst2-ANT in nude mice bearing
HEK-hsst2 tumours
aCoinjection of 20 nmol DOTA-
sst2-ANT.
Organ 1 h 4 h 4 h blockinga 24 h 48 h 72 h
Blood 1.01±0.36 0.19±0.01 0.14±0.04 0.05±0.01 0.02±0.00 0.01±0.00
Heart 0.54±0.24 0.12±0.03 0.09±0.04 0.06±0.00 0.05±0.01 0.02±0.01
Liver 1.07±0.25 0.57±0.11 0.54±0.24 0.32±0.04 0.29±0.02 0.23±0.02
Spleen 0.65±0.12 0.25±0.04 0.24±0.11 0.16±0.05 0.13±0.02 0.12±0.02
Lung 2.60±0.78 0.50±0.08 0.38±0.07 0.15±0.02 0.12±0.03 0.10±0.03
Kidney 12.92±4.12 11.65±1.44 8.40±3.58 5.12±0.78 4.24±0.27 2.15±0.31
Stomach 7.31±1.99 0.85±0.06 0.15±0.06 0.32±0.06 0.26±0.02 0.17±0.03
Intestine 0.80±0.33 0.18±0.04 0.12±0.05 0.08±0.01 0.06±0.01 0.04±0.01
Adrenals 1.79±0.40 0.41±0.31 0.11±0.14 0.34±0.09 0.39±0.15 0.21±0.13
Pancreas 10.35±3.33 0.69±0.08 0.07±0.01 0.12±0.01 0.08±0.02 0.05±0.02
Muscle 0.38±0.06 0.11±0.02 0.05±0.03 0.06±0.02 0.05±0.02 0.03±0.02
Bone 1.92±1.60 0.61±0.39 0.02±0.07 0.39±0.19 0.46±0.45 0.19±0.18
Tumour 25.26±4.00 29.61±5.13 1.70±0.17 19.67±3.39 12.41±0.69 7.02±0.28
Table 4 Tumour-to-nontumour ratios of 111In-DOTA-sst2-ANT in
nude mice bearing HEK-hsst2 tumours
Ratio 1 h 4 h 24 h 48 h 72 h
Tumour-to-blood 25 153 411 596 742
Tumour-to-muscle 67 279 348 275 266
Tumour-to-liver 24 52 61 43 31
Tumour-to-kidney 1.9 2.5 3.8 2.9 3.3
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Fig. 4 In vivo accumulation and washout of 111In-DOTA-sst2-ANT
over time in HEK293 cells expressing different sst receptors (rsst2 rat
sst2, rsst3 rat sst3, hsst2 human sst2). Results are presented as mean ±
SD %IA/g
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the agonist 64Cu-CB-TE2A-TATE in nude mice xenografted
with the rat pancreatic tumour cell line AR42J, despite the
fact that the authors found a 14-fold higher number of
receptor binding sites for the antagonist [7]. As
somatostatin-based radiopeptides are the only family of
radiopeptides having an impact on patient care as diagnostic
agents (SPECT and PET) [11] and in targeted radionuclide
therapy of neuroendocrine tumours [12, 13], we reasoned
that any improvement in this field is worthwhile, and in
particular radioantagonists deserve more scrutiny. We there-
fore studied this peptide more thoroughly. In the present
study we evaluated extensively the performance of 111In-
DOTA-sst2-ANT in cell cultures in vitro and extended the
evaluation of its biodistribution to later time-points. This
was also done in a xenograft model expressing the human
sst2 receptor to ensure that there were no species differences
as found with radiopeptides targeting the gastrin-releasing
peptide receptor [8]. In addition, we studied the pharmaco-
kinetics of 177Lu-DOTA-sst2-ANT to exclude any potential
influence of the radiometal on pharmacological properties
and to determine the potential usefulness of this radioanta-
gonist in therapeutic applications. We also studied the
blocking of kidney uptake with blocking agents used
clinically.
There are several important results from these studies.
The pharmacokinetic data of 111In-DOTA-sst2-ANT clearly
showed that there was no significant difference between
human and rat receptor with regard to tumour uptake and
washout from the tumour resulting in an almost identical
area under the curve. This may be explained by the similar
Bmax values (data not shown) and the high homology of the
human and the rat sst2 receptor [14, 15].
177Lu-DOTA-sst2-
ANT was studied in comparison with 111In-DOTA-sst2-
ANT up to 72 h. In agreement with the results from the
saturation binding studies demonstrating a similar dissocia-
tion constant (Kd) for both (radio)metal-labelled peptides,
the tumour uptake was almost identical for the two radio-
peptides. This indicates no influence of the radiometal on
this DOTA-conjugated antagonist rendering 177Lu-DOTA-
sst2-ANT a promising radiotherapeutic agent. This result is
Table 5 Biodistribution (mean ±
SD %IA/g, n04) of 177
Lu-DOTA-sst2-ANT in nude
mice bearing HEK-rsst2 tumours
aCoinjection of 20 nmol DOTA-
sst2-ANT.
Organ 4 h 4 h blockinga 24 h 48 h 72 h
Blood 0.20±0.02 0.31±0.05 0.06±0.01 0.03±0.00 0.02±0.00
Heart 0.25±0.03 0.12±0.04 0.08±0.03 0.05±0.01 0.02±0.01
Liver 0.80±0.07 0.86±0.10 0.40±0.09 0.30±0.02 0.24±0.05
Spleen 1.03±0.86 0.34±0.05 0.23±0.05 0.14±0.01 0.12±0.03
Lung 2.88±1.54 0.54±0.10 0.44±0.13 0.19±0.03 0.08±0.03
Kidney 10.82±1.76 13.91±1.06 6.03±1.49 3.35±0.56 1.70±0.35
Stomach 17.26±2.39 0.32±0.08 1.83±0.59 0.77±0.02 0.39±0.02
Intestine 0.96±0.37 0.18±0.05 0.28±0.09 0.07±0.02 0.05±0.01
Adrenals 2.85±1.04 0.40±0.25 1.37±0.71 0.48±0.03 0.04±0.03
Pancreas 26.11±7.63 0.21±0.01 1.18±0.46 0.37±0.02 0.26±0.01
Muscle 0.22±0.07 0.10±0.04 0.15±0.07 0.04±0.01 0.03±0.02
Bone 1.06±0.13 0.05±0.04 0.92±0.27 0.36±0.17 0.44±0.08
Tumour 34.90±2.86 1.33±0.19 25.65±6.37 13.57±2.17 7.79±0.68
Table 6 Tumour-to-nontumour ratios of 177Lu-DOTA-sst2-ANT in
nude mice bearing HEK-rsst2 tumours
Ratio 4 h 24 h 48 h 72 h
Tumour-to-blood 175 428 452 390
Tumour-to-muscle 159 171 339 260
Tumour-to-liver 44 64 45 33
Tumour-to-kidney 3.2 4.3 4.1 4.6
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Fig. 5 Biodistribution of 111In-DOTA-sst2-ANT in nude mice bearing
HEK293-rsst2 tumours. Three groups of mice (n03) received lysine
(20 mg) or Gelofusine (4 mg) or PBS (control group) 5 min before the
injection of the radiopeptide. Biodistribution was evaluated 24 h p.i.
and the results are expressed as mean ± SD %IA/g (n03)
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somewhat contrary to the result with another somatostatin-
based radioantagonist [16] when we found distinct differ-
ences in pharmacology depending on radiometal and chela-
tor. The specificity of the radiopeptides in the HEK293-rsst2
and HEK293-hsst2 tumours as well as in sst2-positive tis-
sues, such as the pancreas, was clearly demonstrated by
blocking studies where >90 % blocking was achieved in
all experiments. In an additional study to confirm specificity
a dual tumour model, HEK293-rsst3 in one flank and
HEK293-rsst2 in the other, was used. The uptake in
HEK293-rsst3 tumours was negligible at time-points more
than 4 h p.i. Blood clearance of both radiopeptides was fast
resulting in high tumour-to-blood and tumour-to-normal
organ ratios at early time-points which increased with time
for most organs. The blocking agent did not affect the
uptake in the kidneys, indicating that this uptake is not
receptor-mediated. Gelofusine and lysine can efficiently
reduce the renal uptake of radiopeptides [17, 18] probably
via a different mechanism. Kidney blocking with lysine and
Gelofusine was effective, as expected. Neither agent
blocked tumour uptake but did block kidney uptake by
about 50 %, increasing the tumour-to-kidney ratio about
twofold.
An open question concerning internalization was the
discrepancy – although low – between the lack of internal-
ization found when receptor trafficking is studied using
immunofluorescence microscopy [6] compared to radioli-
gand internalization. In immunofluorescence microscopy-
based internalization experiments natIn-DOTA-sst2-ANT
did not trigger sst2 receptor internalization [6], while in the
radioligand internalization experiments a low internalization
rate was found for the 111In-DOTA-sst2-ANT. It should be
considered that in the immunofluorescence microscopy
experiments, where receptor trafficking is monitored,
the ligand is used in high excess while in the radio-
ligand internalization experiments the radiopeptide con-
centration is far below tumour saturation. Concerning
the internalization of radiolabelled antagonists similar
observations have been made by others. A low degree
of internalization was also detected when 64Cu-CB-
TE2A-sst2-ANT was studied in AR42J cells [7] and in
sst2-positive HCT116 cells [19]. In the present study, no
radiopeptide internalization in HEK293 cells not
expressing sst2 was found. Additionally, pretreatment
of the HEK293-rsst2 cells with hypertonic sucrose,
which is known to prevent receptor endocytosis by
preventing clathrin-coated pit formation [20], distinctly
reduced radiopeptide internalization. These findings are
strong indications of a specific receptor-mediated inter-
nalization process. Why this is not observable if recep-
tor trafficking is studied is not clear at the moment, but
may be a consequence of the different experimental
conditions described above.
The in vitro dissociation experiment was performed to
determine if the slow dissociation of the radiopeptide is the
explanation for the long in vivo tumour residence time. This
was found to be not the case as the residence half-life in the
cell culture experiment was about 10 min. Approximately
90 % of the radiopeptide dissociated within 60 min, while
the remaining 10 % was internalized. Therefore, we con-
clude that microenvironmental phenomena including the
chaotic tumour vessel system are responsible for the long
retention.
Although obtained in a very small number of
patients, the preclinical data showing the superiority of
radiolabelled somatostatin-based antagonists over ago-
nists seem to be translatable to the clinic. 111In-DOTA-
sst2-ANT was studied in an early human use study in
comparison with 111In-DTPA-octreotide (OctreoScan®)
in five patients with (neuro)endocrine tumours [21].
Tumour uptake and in particular the tumour-to-kidney
ratio was clearly in favour of 111In-DOTA-sst2-ANT.
This result is promising and gives hope for improved
diagnostic (SPECT and PET) and therapeutic vectors
targeting sst-positive tumours.
In summary, the radiopeptide 111In-DOTA-sst2-ANT was
previously studied and showed superior pharmacokinetics if
compared to potent agonists. The study reported here
extends the previous studies to new tumour models, the
177Lu-labelled version and extension of the pharmacokinet-
ics to later time-points. The data show that 111In-/177Lu-
DOTA-sst2-ANT are excellent sst2-targeting agents which
deserve translation to trials in patients and indicate the
relevance of these radiopeptides not only in diagnostic im-
aging but also in targeted radionuclide therapy of sst-
positive tumours.
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